BNTX - BioNTech SE
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 104.12 |
| Open | 107.46 |
| Bid | 107.30 x 900 |
| Ask | 108.20 x 900 |
| Day's Range | 106.56 - 109.61 |
| 52 Week Range | 100.08 - 188.99 |
| Volume | |
| Avg. Volume | 701,095 |
| Market Cap | 26.058B |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | 3.98 |
| EPS (TTM) | 27.20 |
| Earnings Date | Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 170.39 |
Fair Value
Related Research
Motley FoolWhy Shares of BioNTech Rose Friday
Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its non-small cell lung cancer therapy candidate. The company focuses on immunotherapies to treat cancer, infectious diseases, and other diseases. BioNTech's shares have been sliding because sales of Comirnaty, the COVID-19 vaccine it developed with Pfizer, are falling.
Investor's Business DailyBioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech said Friday almost a third of patients with a hard-to-treat form of lung cancer responded to its treatment — and BNTX stock popped.
- Reuters
UPDATE 1-BioNTech's OncoC4 partnership off to good start with mid-stage trial results
BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial. The experimental drug, known as gotistobart, was tested on patients with metastatic non-small cell lung cancer which could no longer be helped by a group of so-called checkpoint inhibitor drugs such as Merck & Co's Keytruda. A follow-on trial in the third and last phase of testing typically required for approval would start in the third quarter of this year, BioNTech added in its statement.
GlobeNewswireBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCL
The Wall Street JournalHeard on the Street: Investors Are Too Bearish on Vaccine-Makers
OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](https://www.wsj.com/market-data/quotes/MRNA), [Pfizer](https://www.wsj.com/market-data/quotes/PFE) and [BioNTech](https://www.
The Wall Street JournalVaccine Fatigue Can Give Your Portfolio a Booster
Moderna Pfizer and its partner BioNTech are among the biggest losers in the healthcare sector this year, dropping more than 25% each. The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane. Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech.
ZacksEMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
The Wall Street JournalNext Covid Boosters to Target New Strain
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
BenzingaAmended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
The European Commission (EC) had agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. "The amendment to the existing vaccines supply contract takes into account the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should
- Financial Times
Brussels and Pfizer agree deal to cut supply of Covid vaccines
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
- Reuters
UPDATE 2-EU, Pfizer/BioNTech announce amendment to COVID vaccine contract
The European Union and drugmakers Pfizer and BioNTech said on Friday they had reached a deal to amend a COVID-19 vaccine contract, cutting the number the EU must buy and pushing the delivery deadline to 2026. The agreement, first reported by Reuters earlier on Friday, comes after months of talks and amid pressure on Brussels from EU governments to secure a change to the contract because of a global glut of COVID-19 vaccine doses and low demand for boosters. The amended contract matches "evolving needs", said EU Health Commissioner Stella Kyriakides in a statement.
BenzingaBioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with recommendations by the World Health Organization. Last week, an advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the upcoming winter season. The company said it was on track to introduce a COVID-19 shot by the ea
- Reuters
BioNTech is proceeding with COVID-shot in line with WHO guidance
Germany's BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by the World Health Organization. BioNTech was targeting regulatory approval by the end of the summer to allow for a seasonal vaccination campaign to start in early autumn, CEO and co-founder Ugur Sahin told shareholders at the biotech firm's annual general meeting on Thursday. BioNTech is collaborating on the vaccine with Pfizer in markets outside of greater China.
Motley Fool2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
One of the best investment strategies is to buy shares of companies that are presently beaten down by the market, but in whose businesses you have full confidence for growth over the long term. Then, as the market bids up their valuation over time, you'll get the benefit of both the company's actual growth as well as its strengthening reputation among other investors. Two stocks the market is ignoring today, but could likely become excellent investments in the next decade, are in the biotechnology space.
ZacksAre Options Traders Betting on a Big Move in BioNTech (BNTX) Stock?
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
ReutersCureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine. The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday.
- Reuters
UPDATE 1-CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer the trial. The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine.
InvestorPlace7 Safe Stocks to Buy for an Economic Downward Spiral
For those that want to stay in the market during these ambiguous times, investors should consider safe stocks to buy. Basically, as Wall Street rotates away from risk-on assets, companies exclusively tied to growth and little else run the risk of suffering sharp losses. At the same time, when discussing safe stocks to buy, you often hear a list of the usual suspects. And while those ideas have considerable merit, I decided to change things up with less-orthodox ideas for portfolio protection. Ea
BenzingaWhy Matinas BioPharma Stock Is Sinking Today
BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have ended an mRNA-based collaboration. Matinas reported the update in its Q1 earnings release. The exclusive collaboration with BioNTech was announced just a year ago, with BioNTech paying Matinas an undisclosed amount in exchange for access to Matinas' lipid nanocrystal (LNC) drug delivery platform. BioNTech had also paid Matinas an upfront access fee. The company said that in May 2023, the initial in vivo study of an o
InvestopediaTop Healthcare Stocks for May 2023
Top healthcare stocks include Azenta Inc. for best value, ShockWave Medical for fastest growth, and Viking Therapeutics for most momentum.
- Thomson Reuters StreetEvents
Q1 2023 Matinas BioPharma Holdings Inc Earnings Call
Q1 2023 Matinas BioPharma Holdings Inc Earnings Call
- Reuters
UPDATE 1-BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit
Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients. Results of a trial in the first phase of testing on humans showed that half of the 16 trial participants, who had undergone surgery to remove their tumour, had developed T cells that can potentially recognise cancerous cells and stop them from re-emerging, Nature said in a paper on Wednesday. The readout, which was reported first by BioNTech in June of last year, is adding to evidence that the technology behind COVID-19 vaccines has potential in oncology.
Investor's Business DailyBioNTech Trounces First-Quarter Profit Views, But Covid Declines Will Continue
BioNTech crushed Wall Street's profit views Monday, but shares dipped at the close amid expectations for more drops in Covid vaccine sales.
Motley FoolBioNTech Se (BNTX) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. BioNTech Se (NASDAQ: BNTX)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to the BioNTech first quarter 2023 update call.
